Cures Within Reach For Cancer - Team and Advisors


 Team

 

Laura Kleiman newLaura Kleiman, PhD

Executive Director, Cures Within Reach for Cancer; Scientific Research Director, cBio Center at the Dana-Farber Cancer Institute

Laura obtained a PhD in computational and systems biology from the Massachusetts Institute of Technology. She was an American Cancer Society Postdoctoral Research Fellow at the Massachusetts General Hospital and Harvard Medical School, where she trained in clinical and translational research. Laura subsequently worked as Project Manager at the drug repurposing non-profit GlobalCures, where she led all start-up activities for a Phase III cancer clinical trial. At Dana-Farber, Laura provides leadership and direction for the new cBio Center for computational and systems biology and informatics. She launched Cures Within Reach for Cancer to facilitate the development of promising cancer treatments currently being overlooked due to a lack of profitability.

Contact Laura: laura@cureswithinreach.org

 

Bruce Bloom newBruce Bloom, JD, DDS

CEO, Cures Within Reach

Bruce has 15 years of experience facilitating drug repurposing research for Cures Within Reach, the fiscal sponsor of Cures Within Reach for Cancer. He has spearheaded efforts to establish drug repurposing social impact bonds as a mechanism for funding generic drug clinical trials and has been elected an International Ashoka Fellow, which recognizes social entrepreneurs. Bruce obtained a JD from the IIT Chicago-Kent College of Law and DDS from University of Illinois Medical Center.

 

 

Dale FlandersDale Flanders, PhD 

Director of Strategic Development, Cures Within Reach for Cancer

Dale first learned about repurposing of FDA-approved non-cancer drugs for cancer treatment through GlobalCures, and he is now committed to finding innovative approaches to their funding and development. Dale received his PhD in electrical engineering from MIT in 1978. He is a successful entrepreneur with a long track record of defining new businesses, raising capital, and building successful and profitable companies at the leading edge of technology. After working in research at MIT Lincoln Laboratory, Dale joined Lasertron as the VP of Engineering and R&D and CTO, and as VP of Device Manufacturing. When Lasertron was eventually acquired by Corning, Dale left to found Axsun Technologies. At Axsun, he served as CEO until 2015 and raised over $150 million of investment. Axsun was acquired by a public company, Volcano Corp., in 2008 and Phillips acquired Volcano and Axsun in 2014. Today Axsun is a growing independent company owned by a private equity firm. Since leaving Axsun, Dale has acted as an adviser to and investor in various startup companies in the medical diagnostics and therapy areas. He is the author of more than 100 issued U.S. patents.

 

 

MonikaMonika Odermatt

Monika is an intern at Roche Basel and a Master’s student of health economics and international healthcare management in Zürich, Switzerland. She is very excited about the mission of Cures Within Reach for Cancer and is writing her thesis on the use of social impact bonds to enable clinical trials for repurposed generic drugs.

 

 

 

 


 Advisors

 

Vincent DeVitaVincent DeVita, MD

Author of “The Death of Cancer” and Professor of Medicine at Yale Cancer Center; Formerly Director of the National Cancer Institute, Physician-in-Chief at Memorial Sloan Kettering Cancer Center, and President of the American Cancer Society

“I am happy to help Cures Within Reach for Cancer advance new cancer treatments based on repurposed generic drugs. Generics allow for more flexibility to optimize treatment protocols since they are already FDA approved and typically inexpensive, and possible side effects are well understood. This is especially important for combination therapies, which are complex to develop and costly. Compared to traditional drug development, it should be faster to get repurposed generics to patients who desperately need additional treatment options. Yet, today there is little off-label use and extremely limited funding for the Phase II/III clinical trials from government, cancer foundations, and industry. Even after successful definitive clinical trials, Cures Within Reach for Cancer and their partners will face an additional challenge of changing standard of care, which is usually spearheaded by pharmaceutical companies and is not straightforward for non-profits. I believe that if we can figure out how to improve the way we use the drugs and technologies we already have, we can cure more cancers or at least convert them into chronic, manageable diseases.” 

 

Bob WeinbergRobert Weinberg, PhD

Author of "The Hallmarks of Cancer" and “The Biology of Cancer” textbook; Professor of Biology, MIT; Director, MIT Ludwig Center for Molecular Oncology; Member, Whitehead Institute for Biomedical Research

"My laboratory is studying the role of inflammation, as part of the wound healing response, in cancer metastasis. Our data strongly support the use of NSAIDs at the time of cancer surgery to block deleterious effects induced by wound healing, which may increase the risk of cancer recurrence. I am pleased to support Cures Within Reach for Cancer’s work to advance repurposed generics such as NSAIDs for cancer treatment."

 

David FrankDavid Frank, MD, PhD

Associate Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School

"My laboratory is developing inhibitors of key signaling pathways that drive the malignant behavior of a cancer cell. While we are taking a number of paths to bring these drugs to clinical trials for cancer patients, it soon became apparent that generic drugs that had already been approved for other indications could be very effective at targeting these pathways. The fact that these drugs are already known to be safe at active doses allows us to tremendously accelerate their transition from the lab to the clinic. We have been fortunate to secure funding for small early phase clinical trials to initially evaluate these treatments. However, there are currently no funding mechanisms for the subsequent, larger clinical trials that are critical before these therapies could be used more broadly. As a medical oncologist, I see Cures Within Reach for Cancer as being instrumental in enabling these clinical trials, and filling an essential role for our patients."

 

Skip IrvingSkip Irving, MBA

Member, Board of Directors, Michael J. Fox Foundation for Parkinson’s Research; Managing Director, Stonecliff Advisors; Vice President, Planning, Noveome Biotherapeutics

"I have been working with emerging and established biotechnology and pharmaceutical companies and several of the leading not-for-profit disease foundations for the last 30 years to help them design and implement their drug development strategies. In the 10 years I have been associated with the Michael J. Fox Foundation for Parkinson's Research, the organization has grown dramatically and now funds nearly $80 million in Parkinson’s research. It has changed the paradigm for not-for-profit disease foundations and is a valuable resource for drug development companies and venture funds planning clinical trials for new Parkinson’s drugs. Cures Within Reach for Cancer has the potential for an equally compelling clinical impact. Rapidly advancing treatments for cancer through the repurposing of FDA-approved generic drugs will benefit patients through enhanced efficacy and lower cost of treatment. The data generated to date is impressive and comparable to novel drugs in clinical development. Our classic drug development paradigm does not incentivize the pursuit of repurposed molecules. I am delighted to support Cures Within Reach for Cancer, because, like the Michael J. Fox Foundation and other disease foundations, it expedites the development of entirely new treatment options for cancer patients." 

 

David SontagDavid Sontag, PhD

Assistant Professor, Department of Electrical Engineering and Computer Science and Institute for Medical Engineering and Science, MIT

 “I am very supportive of Cures Within Reach for Cancer’s mission and am happy to provide advice as they develop their drug repurposing KnowledgeBase. My research group aims to transform healthcare using machine learning and artificial intelligence. Retrospective studies are becoming more common with the availability of electronic medical records and advances in data sciences, and they are generating a tremendous amount of new knowledge. For example, we are discovering that FDA approved non-cancer drugs may be beneficial cancer treatments. Cures Within Reach for Cancer plans to systematically identify publications related to repurposed generics for cancer (estimated to be around 10,000 papers), extract treatment and outcome information, and then organize the information so it can be useful for researchers, physicians, and patients. The clinical informatics and natural language processing communities have already built tools that could be 'repurposed' for this project with minimal effort.”

 

Gauthier BoucheGauthier Bouche, MD

Medical Director, Anticancer Fund

 “When we started the Anticancer Fund in Europe in 2009, we carefully evaluated different strategies to bring new treatment options to cancer patients as quickly as possible. We concluded that ‘repurposing’ drugs we already have is the most rewarding way forward. Over the years, as we have unfolded the cancer repurposing literature with our partner GlobalCures, two things have become clear. First, there is a gigantic untapped potential in the arsenal of FDA-approved drugs, with more than 220 highly promising repurposed drugs on our list as of April 2017. Second, we were shocked that repurposed drugs that cured cancer patients or prolonged their survival in randomized clinical trials (the gold standard of evidence-based medicine) have been ignored simply because they lack commercial value. We’re so glad Cures Within Reach for Cancer has launched. We look forward to working together on an international effort to systematically curate the huge amount of existing knowledge, prioritize treatments for further clinical development, raise funds to enable clinical trials, and remove the barriers to adoption as standard of care.”

 

Lora WilliamsLora Williams

Breast Cancer Survivor; Writer; Yoga, Meditation, and Livestrong Instructor

"I was diagnosed with Stage 2, Grade II ER/PR positive, HER2 negative breast cancer in 2015, and I subsequently had a double mastectomy. It wasn’t until several months after surgery that I discovered, through GlobalCures, that a one-time pre-surgical infusion of the NSAID ketorolac showed significant promise in reducing the risk of metastatic recurrence post-surgically. I also learned that, because this drug is generic, pharmaceutical companies are not motivated to fund the necessary clinical trials because they will not make enough profit from the sale of the drug for its new use to justify the expense of the trials. I work with cancer survivors in my Livestrong classes, and I am heartbroken every time I consider the number of people I know with metastases who might have been helped by treatments like ketorolac that were not available to them because of this funding problem – and I hope I will not become one of them. I’m optimistic that Cures Within Reach for Cancer will find a way to bring these drugs into clinical trials and make beneficial, low-toxicity treatments available to patients."

 

Lars and Dyanne SøraasLars and Dyanne Søraas

Patient Advocates and Lung Cancer Research Advocates

"When Dyanne was diagnosed with stage IV lung cancer in 2015, we decided to think outside of the box and consider all possible treatment options. From reading many scientific and clinical papers, we found treatments that were not offered to Dyanne but seemed potentially very promising. Among these were some repurposed non-cancer generics which appeared like they might be effective, and have few side effects and low cost. We brought these papers to her oncologist and asked if it would be possible to get the drugs prescribed. The reply was that, although the early clinical data looked promising, the hospital would not support their use until large clinical trials had been conducted. We then investigated why these trials were never started and learned that it is because the treatments will not be profitable for pharmaceutical companies, so they do not want to fund the trials. It is still a mystery to us, however, why government-funded hospitals don’t do many more trials with such generic drugs. As a society, we have to find a solution to this problem so cancer patients worldwide can benefit from these very promising and inexpensive therapies. We wholeheartedly support Cures Within Reach for Cancer's ambitious goals to increase awareness of this gap in our drug development system and find innovative ways to advance these therapies."

  

CWR for Cancer Home Button

Sign up for our eNewsletter today!

 

First Name




Search

Cures Within Reach

info@cureswithinreach.org

 

Thursday the 14th. copyright 2015 Cures Within Reach.